HCW Biologics posts Q2 2025 results via press release

HCW Biologics Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended June 30, 2025.

Accepted by SEC EDGAR 08/14/2025 - 05:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

HCW Biologics Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended June 30, 2025. The company issued this press release on August 14, 2025, and attached it as Exhibit 99.1. The information in this report, including the exhibit, is designated as furnished rather than filed under securities law, which limits certain legal liabilities and incorporation into other registration statements.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HCW Biologics Inc. (HCWB) disclose in this 8-K filing?

HCW Biologics Inc. disclosed that it issued a press release announcing financial results for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1 and is furnished, not filed, under securities law definitions.

When did HCW Biologics (HCWB) release its quarterly financial results?

HCW Biologics released its quarterly financial results on August 14, 2025, through a press release. This press release, covering the quarter ended June 30, 2025, is attached to the report as Exhibit 99.1 for investor reference.

Which period do HCW Biologics’ (HCWB) announced results cover?

The company’s announced results cover the quarter ended June 30, 2025. These results are detailed in a press release that HCW Biologics furnished as Exhibit 99.1, referenced in the current report filed under Item 2.02.

How is the HCW Biologics (HCWB) press release treated under securities laws?

The press release and related information are treated as furnished, not filed, under the Securities Exchange Act of 1934. This means they are not subject to Section 18 liabilities or automatically incorporated into other Securities Act or Exchange Act filings.

What exhibits are attached to the HCW Biologics (HCWB) 8-K?

The filing includes Exhibit 99.1, a press release dated August 14, 2025, announcing quarterly financial results, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document for technical reporting compliance.

Who signed the HCW Biologics (HCWB) 8-K report?

The report was signed on behalf of HCW Biologics Inc. by Hing C. Wong. He is identified as the Founder and Chief Executive Officer and signed the document dated August 14, 2025, thereby authorizing the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001828673false00018286732025-08-142025-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

HCW Biologics Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40591	82-5024477
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2929 N. Commerce Parkway
Miramar, Florida				33025
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 954 842-2024

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		HCWB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, HCW Biologics Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release dated August 14, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			HCW BIOLOGICS INC.
Date:	August 14, 2025	By:	/s/ Hing C. Wong
			Hing C. Wong Founder and Chief Executive Officer